Severe HIV-1 encephalitis and development of cerebral Non-Hodgkin lymphoma in a patient with persistent strong HIV-1 replication in the brain despite potent HAART - Case report and review of the literature

European Journal of Medical Research

Volumn 10, Issue 7, 2005, Pages 309-316

  Baeuerle, Michael ^a   Schmitt Haendle, M ^a   Taubald, A ^a   Mueller, S ^a   Walter, H ^a   Pfeiffer, C ^a   Manger, B ^a   Harrer, T ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

HAART; HIV 1 encephalitis; HIV 1 replication; Non Hodgkin lymphoma

Indexed keywords

AMPRENAVIR; FOSCARNET; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; SAQUINAVIR; STAVUDINE; TENOFOVIR;

ADULT; ARTICLE; BRAIN LYMPHOMA; BRAIN RADIATION; CASE REPORT; COGNITIVE DEFECT; DEATH; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG POTENCY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NONHODGKIN LYMPHOMA; VIREMIA; VIRUS ENCEPHALITIS; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ADULT; AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAIN; BRAIN NEOPLASMS; FATAL OUTCOME; HIV-1; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, NON-HODGKIN; MAGNETIC RESONANCE IMAGING; MALE; VIRUS REPLICATION;

EID: 23644448615     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (121)

1. Perelson, A. S., et al. (1997). "Decay characteristics of HIV-1-infected compartments during combination therapy." Nature 387(6629): 188-91.
2. Dore, G. J., et al. (1999). "Changes to AIDS dementia complex in the era of highly active antiretroviral therapy." Aids 13(10): 1249-53.
3. Dore, G. J., et al. (2002). "Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Australia." J Acquir Immune Defic Syndr 29(4): 388-95.
4. Eggers, C., et al. (2003). "Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration." Aids 17(13): 1897-906.
5. Schacker, T., et al. (1996). "Clinical and epidemiologic features of primary HIV infection." Ann Intern Med 125(4): 257-64.
6. Davis, L. E., et al. (1992). "Early viral brain invasion in iatrogenic human immunodeficiency virus infection." Neurology 42(9): 1736-9.
7. Janssen, R. S. (1997). Epidemiology and neuroepidemiology of human immunodeficiency virus infection. AIDS and the nervous system. L. R. Berger JR. Philadelphia, Lipincott-Raven. 21.
8. Ellis, R. J., et al. (1997). "Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group." Ann Neurol 42(5): 679-88.
9. Gisslen, M., et al. (1999). "Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection." J Acquir Immune Defic Syndr 21(4): 271-6.
10. McArthur, J. C., et al. (1997). "Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain." Ann Neurol 42(5): 689-98.
11. Eggers, C. C., et al. (1999). "HIV infection of the central nervous system is characterized by rapid turnover of viral RNA in cerebrospinal fluid." J Acquir Immune Defic Syndr Hum Retrovirol 20(3): 259-64.
12. Bacellar, H., et al. (1994). "Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992." Neurology 44(10): 1892-900.
13. Hengge, U. R., et al. (1998). "HIV-1 RNA levels in cerebrospinal fluid and plasma correlate with AIDS dementia." Aids 12(7): 818-20.
14. Brew, B. J., et al. (1997). "Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage." J Infect Dis 175(4): 963-6.
15. Cinque, P., et al. (1998). "Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication." Aids 12(11): 1327-32.
16. Gisslen, M. and L. Hagberg (2001). "Antiretroviral treatment of central nervous system HIV-1 infection: a review." HIV Med 2(2): 97-104.
17. Foudraine, N. A., et al. (1998). "Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine." Lancet 351(9115): 1547-51.
18. Gisslen, M., et al. (1997). "HIV-1 RNA is not detectable in the cerebrospinal fluid during antiretroviral combination therapy." Aids 11(9): 1194.
19. Tozzi, V., et al. (1999). "Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment." Aids 13(14): 1889-97.
20. Cohen, R. A., et al. (2001). "Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women." Aids 15(3): 341-5.
21. Deutsch, R., et al. (2001). "AIDS-associated mild neurocognitive impairment is delayed in the era of highly active antiretroviral therapy." Aids 15(14): 1898-9.
22. Stankoff, B., et al. (2001). "Clinical and spectroscopic improvement in HIV-associated cognitive impairment." Neurology 56(1): 112-5.
23. Sacktor, N., et al. (2002). "HIV-associated cognitive impairment before and after the advent of combination therapy." J Neurovirol 8(2): 136-42.
24. Kerza-Kwiatecki, A. P. and S. Amini (1999). "CNS as an HIV-1 reservoir; BBB and drug delivery." J Neurovirol 5(2): 113-4.
25. Price, R. W. and S. Staprans (1997). "Measuring the "viral load" in cerebrospinal fluid in human immunodeficiency virus infection: window into brain infection?" Ann Neurol 42(5): 675-8.
26. Antinori, A., et al. (2002). "Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients." Aids 16(14): 1867-76.
27. Ammassari, A., et al. (2000). "AIDS-related focal brain lesions in the era of highly active antiretroviral therapy." Neurology 55(8): 1194-200.
28. Langford, T. D., et al. (2002). "Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy." Aids 16(7): 1019-29.
29. Cinque, P., et al. (1998). "Cerebrospinal fluid HIV-1 RNA levels: correlation with HIV encephalitis." Aids 12(4): 389-94.
30. Staprans, S., et al. (1999). "Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection." Aids 13(9): 1051-61.
31. Bossi, P., et al. (1998). "The level of human immunodeficiency virus (HIV) type 1 RNA in cerebrospinal fluid as a marker of HIV encephalitis." Clin Infect Dis 26(5): 1072-3.
32. Garcia, F., et al. (1999). "Cerebrospinal fluid HIV-1 RNA levels in asymptomatic patients with early stage chronic HIV-1 infection: support for the hypothesis of local virus replication." Aids 13(12): 1491-6.
33. Kravcik, S., et al. (1999). "Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir." J Acquir Immune Defic Syndr 21(5): 371-5.
34. Polis, M. A., et al. (2003). "Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent fourdrug antiretroviral regimen." Aids 17(8): 1167-72.
35. Powderly, W. G. (2000). "Current approaches to treatment for HIV-1 infection." J Neurovirol 6(Suppl 1): S8-S13.
36. Wong, J. K., et al. (1997). "In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues." J Virol 71(3): 2059-71.
37. Budka, H. (1991). "Neuropathology of human immunodeficiency virus infection." Brain Pathol 1 (3): 163-75.
38. Bell, J. E., et al. (1993). "Human immunodeficiency virus and the brain: investigation of virus load and neuropathologic changes in pre-AIDS subjects." J Infect Dis 168(4): 818-24.
39. Koyanagi, Y., et al. (1987). "Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms." Science 236(4803): 819-22.
40. Massari, F. E., et al. (1990). "In vivo T lymphocyte origin of macrophage-tropic strains of HIV. Role of monocytes during in vitro isolation and in vivo infection." J Immunol 144(12): 4628-32.
41. Liu, N. Q., et al. (2002). "Human immunodeficiency virus type 1 enters brain microvascular endothelia by macropinocytosis dependent on lipid rafts and the mitogen-activated protein kinase signaling pathway." J Virol 76(13): 6689-700.
42. Mayne, M., et al. (2000). "Release of calcium from inositol 1,4,5-trisphosphate receptor-regulated stores by HIV-1 Tat regulates TNF-alpha production in human macrophages." J Immunol 164(12): 6538-42.
43. Mayhan, W. G. (2002). "Cellular mechanisms by which tumor necrosis factor-alpha produces disruption of the blood-brain barrier." Brain Res 927(2): 144-52.
44. Liu, Y., et al. (2000). "Analysis of human immunodeficiency virus type 1 gp160 sequences from a patient with HIV dementia: evidence for monocyte trafficking into brain." J Neurovirol 6(Suppl 1): S70-81.
45. Martin, C., et al. (1998). "Cerebrospinal fluid mononuclear cell counts influence CSF HIV-1 RNA levels." J Acquir Immune Defic Syndr Hum Retrovirol 17(3): 214-9.
46. Georgsson, G. (1994). "Neuropathologic aspects of lentiviral infections." Ann N Y Acad Sci 724: 50-67.
47. Romero, I. A., et al. (2000). "Interactions between brain endothelial cells and human T-cell leukemia virus type 1-infected lymphocytes: mechanisms of viral entry into the central nervous system." J Virol 74(13): 6021-30.
48. Chen, W.,et al. (2002). "Development of a human neuronal cell model for human immunodeficiency virus (HIV)-infected macrophage-induced neurotoxicity: apoptosis induced by HIV type 1 primary isolates and evidence for involvement of the Bcl-2/Bcl-xL-sensitive intrinsic apoptosis pathway." J Virol 76(18): 9407-19.
49. Bragg, D. C., et al. (2002). "Infection of the choroid plexus by feline immunodeficiency virus." J Neurovirol 8(3): 211-24.
50. Ellis, R. J., et al. (2000). "Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources." Neurology 54(4): 927-36.
51. Shieh, J. T., et al. (1998). "Chemokine receptor utilization by human immunodeficiency virus type 1 isolates that replicate in microglia." J Virol 72(5): 4243-9.
52. He, J., et al. (1997). "CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia." Nature 385(6617): 645-9.
53. Choe, H., et al. (1996). "The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates." Cell 85(7): 1135-48.
54. Albright, A. V., et al. (1999). "Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates." J Virol 73(1): 205-13.
55. Bagasra, O., et al. (1996). "Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry." Aids 10(6): 573-85.
56. Gorry, P. R., et al. (2001). "Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity." J Virol 75(21): 10073-89.
57. Wiley, C. A., et al. (1986). "Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients." Proc Natl Acad Sci U S A 83(18): 7089-93.
58. Chang, J., et al. (1998). "Unique HIV type 1 V3 region sequences derived from six different regions of brain: region-specific evolution within host-determined quasispecies." AIDS Res Hum Retroviruses 14(1): 25-30.
59. Donaldson, Y. K., et al. (1994). "In vivo distribution and cytopathology of variants of human immunodeficiency virus type 1 showing restricted sequence variability in the V3 loop." J Virol 68(9): 5991-6005.
60. Gartner, S., et al. (1997). "Gp120 sequence variation in brain and in T-lymphocyte human immunodeficiency virus type 1 primary isolates." J Hum Virol 1(1): 3-18.
61. Hughes, E. S., et al. (1997). "Investigation of population diversity of human immunodeficiency virus type 1 in vivo by nucleotide sequencing and length polyrmorphism analysis of the V1/ V2 hypervariable region of env." J Gen Virol 78(Pt 11): 2871-82.
62. Korber, B. T., et al. (1994). "Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences." J Virol 68(11): 7467-81.
63. Shapshak, P., et al. (1999). "Independent evolution of HIV type 1 in different brain regions." AIDS Res Hum Retroviruses 15(9): 811-20.
64. van't Wout, A. B., et al. (1998). "Analysis of the temporal relationship between human immunodeficiency virus type 1 quasispecies in sequential blood samples and various organs obtained at autopsy." J Virol 72(1): 488-96.
65. Power, C., et al. (1995). "Distinct HIV-1 env sequences are associated with neurotropism and neurovirulence." Curt Top Microbiol Immunol 202: 89-104.
66. Jordan, C. A., et al. (1991). "Infection of brain microglial cells by human immunodeficiency virus type 1 is CD4 dependent." J Virol 65(2): 736-42.
67. Chan, S. Y., et al. (1999). "V3 recombinants indicate a central role for CCR5 as a coreceptor in tissue infection by human immunodeficiency virus type 1." J Virol 73 (3): 2350-8.
68. Strizki, J. M., et al. (1996). "Infection of primary human microglia and monocyte-derived macrophages with human immunodeficiency virus type 1 isolates: evidence of differential tropism." J Virol 70(11): 7654-62.
69. Lafeuillade, A., et al. (1996). "HIV-1 replication in the plasma and cerebrospinal fluid." Infection 24(5): 367-71.
70. Morris, L., et al. (1998). "High human immunodeficiency virus type 1 RNA load in the cerebrospinal fluid from patients with lymphocytic meningitis." J Infect Dis 177(2): 473-6.
71. Sei, S., et al. (1996). "Evaluation of human immunodeficiency virus (HIV) type 1 RNA levels in cerebrospinal fluid and viral resistance to zidovudine in children with HIV encephalopathy." J Infect Dis 174(6): 1200-6.
72. Gisslen, M., et al. (1998). "Cerebrospinal fluid viral load in HIV-1-infected patients without antiretroviral treatment: a longitudinal study." J Acquir Immune Defic Syndr Hum Retrovirol 17(4): 291-5.
73. Di Stefano, M., et al. (1998). "Neurological disorders during HIV-1 infection correlate with viral load in cerebrospinal fluid but not with virus phenotype." Aids 12(7): 737-43.
74. Lazarini, F., et al. (1997). "Human immunodeficiency virus type 1 DNA and RNA load in brains of demented and non-demented patients with acquired immunodeficiency syndrome." J Neurovirol 3(4): 299-303.
75. Johnson, R. T., et al. (1996). "Quantitation of human immunodeficiency virus in brains of demented and nondemented patients with acquired immunodeficiency syndrome." Ann Neurol 39(3): 392-5.
76. Vazeux, R., et al. (1992). "Low levels of human immunodeficiency virus replication in the brain tissue of children with severe acquired immunodeficiency syndrome encephalopathy." Am J Pathol 140(1):137-44.
77. Eggers, C.,et al. (2000). "Rapid clearance of human immunodeficiency virus type 1 from ventricular cerebrospinal fluid during antiretroviral treatment." Ann Neurol 47(6): 816-9.
78. Pialoux, G., et al. (1997). "Central nervous system as a sanctuary for HIV-1 infection despite treatment with zidovudine, lamivudine and indinavir." Aids 11(10): 1302-3.
79. Gisslen, M., et al. (1998). "Neurological efficacy of stavudine, zidovudine, and lamivudine." Lancet 352(9125): 402-3.
80. Gisslen, M., et al. (1998). "HIV-1 RNA detectable with ultra-sensitive quantitative polymerase chain reaction in plasma but not in cerebrospinal fluid during combination treatment with zidovudine, lamivudine and indinavir." Aids 12(1): 114-6.
81. McArthur, J. C., et al. (1999). "Human immunodeficiency virus-associated dementia." Semin Neurol 19(2): 129-50.
82. Abdulle, S., et al. (2002). "Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection." Aids 16(16): 2145-9.
83. Brew, B. J., et al. (1996). "Predictive markers of AIDS dementia complex: CD4 cell count and cerebrospinal fluid concentrations of beta 2-microglobulin and neopterin." J Infect Dis 174(2): 294-8.
84. Schrager, L. K. and M. P. D'Souza (1998). "Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy." Jama 280(1): 67-71.
85. Enting, R. H., et al. (1998). "Antiretroviral drugs and the central nervous system." Aids 12(15): 1941-55.
86. McDowell, J. A., et al. (1999). "Pharmacokinetics of [(14)C]-abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study." Antimicrob Agents Chemother 43(12): 2855-61.
87. Burger, D. M., et al. (1993). "Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV." Aids 7(12): 1581-7.
88. Burger, D. M., et al. (1995). "Study on didanosine concentrations in cerebrospinal fluid. Implications for the treatment and prevention of AIDS dementia complex." Pharm World Sci 17(6): 218-21.
89. Haworth, S. J., et al. (1998). "A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults." J Acquir Immune Defic Syndr Hum Retrovirol 17(3): 235-8.
90. Tashima, K. T., et al. (1999). "Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy." J Infect Dis 180(3): 862-4.
91. Aweeka, F., et al. (1999). "Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1 - infected patients with and without AIDS dementia complex." J Acquir Immune Defic Syndr Hum Retrovirol 20(1): 39-43.
92. Martin, C., et al. (1999). "Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system." Aids 13(10): 1227-32.
93. Lanier, E. R., et al. (2001). "HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir." Aids 15(6): 747-51.
94. Venturi, G., et al. (2000). "Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples." J Infect Dis 181(2): 740-5.
95. Cunningham, P. H., et al. (2000). "Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid." Aids 14(13): 1949-54.
96. Bratanich, A. C., et al. (1998). "Brain-derived HIV-1 tat sequences from AIDS patients with dementia show increased molecular heterogeneity." J Neurovirol 4(4): 387-93.
97. Adamson, D. C., et al. (1999). "Mechanisms and structural determinants of HIV-1 coat protein, gp41-induced neurotoxicity." J Neurosci 19(1): 64-71.
98. Johnston, J. B., et al. (2001). "HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors." Ann Neurol 49(2): 230-41.
99. Kaul, M. and S. A. Lipton (1999). "Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis." Proc Natl Acad Sci U S A 96(14): 8212-6.
100. Barks, J. D., et al. (1997). "gp120, a human immunodeficiency virus-1 coat protein, augments excitotoxic hippocampal injury in perinatal rats." Neuroscience 76(2): 397-409.
101. Dreyer, E. B., et al. (1990). "HIV-1 coat protein neurotoxicity prevented by calcium channel antagonists." Science 248(4953): 364-7.
102. Kaiser, P. K., et al. (1990). "Neuronal injury due to HIV-1 envelope protein is blocked by anti-gp120 antibodies but not by anti-CD4 antibodies." Neurology 40(11): 1757-61.
103. Kanmogne, G. D., et al. (2002). "HIV-1 gp120 proteins and gp160 peptides are toxic to brain endothelial cells and neurons: possible pathway for HIV entry into the brain and HIV-associated dementia." J Neuropathol Exp Neurol 61(11): 992-1000.
104. Lannuzel, A., et al. (1997). "Human immunodeficiency virus type 1 and its coat protein gp120 induce apoptosis and activate JNK and ERK mitogen-activated protein kinases in human neurons." Ann Neurol 42(6): 847-56.
105. Giulian, D., et al. (1993). "The envelope glycoprotein of human immunodeficiency virus type 1 stimulates release of neurotoxins from monocytes." Proc Natl Acad Sci U S A 90(7): 2769-73.
106. Pattarini, R., et al. (1998). "The human immunodeficiency virus-1 envelope protein gp120 binds through its V3 sequence to the glycine site of N-methyl-D-aspartate receptors mediating noradrenaline release in the hippocampus." Neuroscience 87(1): 147-57.
107. Shrikant, P., et al. (1996). "HIV glycoprotein 120 enhances intercellular adhesion molecule-1 gene expression in glial cells. Involvement of Janus kinase/signal transducer and activator of transcription and protein kinase C signaling pathways." J Immunol 156(3): 1307-14.
108. Nath, A., et al. (1996). "Identification of a human immunodeficiency virus type 1 Tat epitope that is neuroexcitatory and neurotoxic." J Virol 70(3): 1475-80.
109. Prendergast, M. A., et al. (2002). "Neurotoxic effects of the human immunodeficiency virus type-1 transcription factor Tat require function of a polyamine sensitive-site on the N-methyl-D-aspartate receptor." Brain Res 954(2): 300-7.
110. Conant, K., et al. (1998). "Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia." Proc Natl Acad Sci U S A 95(6): 3117-21.
111. Smith, D. G., et al. (2001). "Quinolinic acid is produced by macrophages stimulated by platelet activating factor, Nef and Tat." J Neurovirol 7(1): 56-60.
112. Gelbard, H. A., et al. (1994). "Platelet-activating factor: a candidate human immunodeficiency virus type 1-induced neurotoxin." J Virol 68(7): 4628-35.
113. Tyor, W. R., et al. (1992). "Cytokine expression in the brain during the acquired immunodeficiency syndrome." Ann Neurol 31(4): 349-60.
114. Sato-Matsumura, K. C., et al. (1998). "Development of HIV encephalitis in AIDS and TNF-alpha regulatory elements." J Neuroimmunol 91(1-2): 89-92.
115. Wesselingh, S. L., et al. (1993). "Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dementia." Ann Neurol 33(6): 576-82.
116. Wilt, S. G., et al. (1995). "In vitro evidence for a dual role of tumor necrosis factor-alpha in human immunodeficiency virus type 1 encephalopathy." Ann Neurol 37(3): 381-94.
117. Westmoreland, S. V., et al. (1996). "Toxicity of TNF alpha and platelet activating factor for human NT2N neurons: a tissue culture model for human immunodeficiency virus dementia." J Neurovirol 2(2): 118-26.
118. Rhodes, R. H. (1993). "Histopathologic features in the central nervous system of 400 acquired immunodeficiency syndrome cases: implications of rates of occurrence." Hum Pathol 24(11): 1189-98.
119. Rostad, S. W., et al. (1987). "Human immunodeficiency virus (HIV) infection in brains with AIDS-related leukoencephalopathy." AIDS Res Hum Retroviruses 3(4): 363-73.
120. Luer, W., et al. (1994). "Acute diffuse leukoencephalitis in HIV-1 infection." J Neurol Neurosurg Psychiatry 57(1): 105-7.
121. Anders, K. H., et al. (1993). "Multifocal necrotizing leukoencephalopathy with pontine predilection in immunosuppressed patients: a clinicopathologic review of 16 cases." Hum Pathol 24(8): 897-904.